The CAFC’s Amgen v Sanofi decision spells trouble for broad functional patent claims

The CAFC’s much-anticipated ruling has major implications for antibody patents and continues the court’s trend of imposing a tough enablement standard for genus claims

Enter your details below to log into your account.

Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.

Adam Houldsworth

Author | Life sciences reporter

[email protected]

Twitter

18 Sep 2021

@IAM_Alerts IP and licensing failures are holding back adoption of new video codecs, says Micky Minhas in this week’s Saturday… https://t.co/9mEmAimuL4 Read more

17 Sep 2021

@IAM_Alerts RT @AMorrisReports: Recent #FTC announcement beefing up investigative powers & targeting alleged #IP abuses signals another Biden administr… Read more

17 Sep 2021

@IAM_Alerts RT @AMorrisReports: This is blowing my mind. 6G??? Sign me up! https://t.co/yM05XY1dDf @IAM_Alerts https://t.co/0iCAh22EQs Read more

17 Sep 2021

@IAM_Alerts $300 million Bausch Health settlement demonstrates the huge sums at stake in reverse payment disputes:… https://t.co/fsfG5fEp4x Read more

The CAFC’s Amgen v Sanofi decision spells trouble for broad functional patent claims

Returning user?

Want to read more?

Adam Houldsworth

TAGS

Twitter